Apimeds Pharmaceuticals Us Stock Buy Hold or Sell Recommendation
| APUS Stock | 2.18 0.11 5.31% |
Slightly above 54% of Apimeds Pharmaceuticals' private investors are presently thinking to get in. The analysis of overall sentiment of trading Apimeds Pharmaceuticals US stock suggests that some investors are interested at this time. Apimeds Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Apimeds Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Comfort Level 54
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Apimeds Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Apimeds Pharmaceuticals US.
News SentimentNeutral | Hype SentimentBullish | Insider SentimentWaiting |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Apimeds Pharmaceuticals US is 'Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Apimeds Pharmaceuticals US given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Apimeds Pharmaceuticals US, the advice is generated through an automated system that utilizes algorithms and statistical models.
Execute Apimeds Pharmaceuticals Buy or Sell Advice
The Apimeds recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Apimeds Pharmaceuticals US. Macroaxis does not own or have any residual interests in Apimeds Pharmaceuticals US or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Apimeds Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Mild | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Moderate | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Apimeds Pharmaceuticals Trading Alerts and Improvement Suggestions
| Apimeds Pharmaceuticals is way too risky over 90 days horizon | |
| Apimeds Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Apimeds Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (1.39 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Apimeds Pharmaceuticals generates negative cash flow from operations | |
| Apimeds Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| About 82.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: APUS Reimagines Higher Education to Continue Preparing Tomorrows Leaders |
Apimeds Pharmaceuticals Returns Distribution Density
The distribution of Apimeds Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Apimeds Pharmaceuticals' future price movements. The chart of the probability distribution of Apimeds Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Apimeds Pharmaceuticals US price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Apimeds Pharmaceuticals returns is essential to provide solid investment advice for Apimeds Pharmaceuticals.
| Mean Return | 0.71 | Value At Risk | -14.12 | Potential Upside | 15.05 | Standard Deviation | 9.53 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Apimeds Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Apimeds Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Apimeds Pharmaceuticals or Capital Markets sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Apimeds Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Apimeds stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.52 | |
β | Beta against Dow Jones | 2.71 | |
σ | Overall volatility | 9.61 | |
Ir | Information ratio | 0.07 |
Apimeds Pharmaceuticals Volatility Alert
Apimeds Pharmaceuticals US is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Apimeds Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Apimeds Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Apimeds Pharmaceuticals Fundamentals Vs Peers
Comparing Apimeds Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Apimeds Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Apimeds Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Apimeds Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Apimeds Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Apimeds Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Apimeds Pharmaceuticals to competition |
| Fundamentals | Apimeds Pharmaceuticals | Peer Average |
| Return On Asset | -4.09 | -0.14 |
| Current Valuation | 21.11 M | 16.62 B |
| Shares Outstanding | 11.58 M | 571.82 M |
| Shares Owned By Insiders | 81.96 % | 10.09 % |
| Number Of Shares Shorted | 3.22 K | 4.71 M |
| EBITDA | (1.27 M) | 3.9 B |
| Net Income | (1.39 M) | 570.98 M |
| Total Debt | 596.84 K | 5.32 B |
| Book Value Per Share | (0.22) X | 1.93 K |
| Cash Flow From Operations | (733.53 K) | 971.22 M |
| Short Ratio | 0.01 X | 4.00 X |
| Earnings Per Share | (0.13) X | 3.12 X |
| Number Of Employees | 2 | 18.84 K |
| Market Capitalization | 24.31 M | 19.03 B |
| Total Asset | 13.06 K | 29.47 B |
| Retained Earnings | (4.39 M) | 9.33 B |
| Working Capital | (1.01 M) | 1.48 B |
| Net Asset | 13.06 K |
Note: Acquisition by Erik Emerson of 215000 shares of Apimeds Pharmaceuticals at 1.92 subject to Rule 16b-3 [view details]
Apimeds Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Apimeds . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Apimeds Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Apimeds Pharmaceuticals US? Buying financial instruments such as Apimeds Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Apimeds Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Volatility ETFs Thematic Idea Now
Volatility ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Volatility ETFs theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Volatility ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Apimeds Stock Analysis
When running Apimeds Pharmaceuticals' price analysis, check to measure Apimeds Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apimeds Pharmaceuticals is operating at the current time. Most of Apimeds Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apimeds Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apimeds Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apimeds Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.